Keywords: oscient, loss, doubles, 7m, usa, pharmaceuticals, fourth-quarter
Oscient's 2008 loss more than doubles to $64.7M
Article | 03 April 2009
The USA's Oscient Pharmaceuticals' fourth-quarter 2008 net loss narrowed to $11.5 million, or $0.50 per share from $14.7 million, or $1.08 per share in the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
